GET THE APP

Management of myofacial pain associated with severe bruxism with type A botulinum toxin (lantox): a twelve month follow-up| Abstract

s├╝perbetin

Management of myofacial pain associated with severe bruxism with type A botulinum toxin (lantox): a twelve month follow-up

Abstract

Germ├â┬â├ć┬ĺ├â┬é├é┬ín Betancur, Juan Pablo San├â┬â├ć┬ĺ├â┬é├é┬şn, Gustavo Ortiz, Pablo Correa

Numerous treatment alternatives have been suggested for the management of bruxism and myofascial pain with variable results, including the local app lication of botulinum toxin; however few studies ha ve been reported and with limited sample size. The obje ctive of this study was to evaluate the clinical efficiency of botulinum toxin type A for the treatm ent of patients with myofascial pain associated wit h severe bruxism. An interventional, blind, longitudi nal twelve month study was carried out; sample size consisted of forty patients with a diagnosis of myo fascial pain associated with severe bruxism on whom botulinum toxin type A was applied; patients w ere evaluated prior to application at 3, 6, 9 and 1 2 months and variables including age, sex, spontaneou s and provoked pain, mandibular opening, mandibular deviation and presence of joint noises w ere considered. 77.7% of the sample consisted of women with an average age of 33.56 ± 12.17 years ol d. 80.5% reported improvement for both spontaneous and provoked pain during treatment, out of which 51.7% presented increased pain 3 and 6 months, 13.7% increased pain between 6 and 9 mont hs and 3.4% between 9 and 12 months. Application of botulinum toxin type A is a safe an d effective treatment for myofascial pain associate d with severe bruxism and its therapeutic effect requ ires new applications every three to six months for its effectiveness to persist.

Share this article

tempobet

tempobet giri┼čbursa escort

tempobet giri┼č

tempobet giri┼č linki tipobet e yeni giri┼č tipobet e yeni giri┼č tipobet son giri┼č s├╝pertotobet g├╝ncel